Sage Therapeutics and Biogen Announce Positive, One-Year Zuranolone 50 mg Data in the Ongoing Open-Label SHORELINE Study in Patients with MDD

In the zuranolone 50 mg cohort, the majority of patients who responded to an initial 14-day course received only one two-week course of treatment during the study and nearly 80% received only one or... | December 1, 2021

Related Keywords

Japan ,Priya Singhal ,Barry Greene ,Walter Gilbert ,Charles Weissmann ,Heinz Schaller ,Kenneth Murray ,Linkedin ,Twitter ,Regulatory Sciences ,Biogen Inc ,Nasdaq ,Exchange Commission ,Us Food Drug Administration ,Sage Therapeutics Inc ,Youtube ,Facebook ,Sage Therapeutics ,Hamilton Rating Scale ,Chief Executive Officer ,Global Safety ,Interim Head ,Montgomery Asberg Depression Rating Scale ,Columbia Suicide Severity Rating Scale ,Major Depressive Disorder ,Breakthrough Therapy Designation ,Nobel Prize ,Today Biogen ,Private Securities Litigation Reform Act ,Quarterly Report ,Biogen Inc Stock Exchange ,News ,Information ,Press Release ,N ,The ,Zuranolone , 0 ,G ,Majority ,F ,Patients ,Who ,Esponded ,O ,Nitial ,Course ,Eceived ,Only ,One ,Treatment ,During ,Study ,End ,Early ,Ne Biib Us09062x1037 ,